Simcere Pharmaceutical Group Limited (HKG:2096)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
12.48
+0.22 (1.79%)
Jun 6, 2025, 4:08 PM HKT
102.60%
Market Cap 30.88B
Revenue (ttm) 7.06B
Net Income (ttm) 780.21M
Shares Out 2.47B
EPS (ttm) 0.31
PE Ratio 40.44
Forward PE 24.24
Dividend 0.18 (1.43%)
Ex-Dividend Date Jun 18, 2025
Volume 17,664,829
Average Volume 17,770,611
Open 12.26
Previous Close 12.26
Day's Range 11.84 - 12.62
52-Week Range 5.08 - 13.22
Beta 0.57
RSI 71.73
Earnings Date Aug 21, 2025

About HKG:2096

Simcere Pharmaceutical Group Limited engages in the research, development, manufacture, and sale of pharmaceutical products to distributors, pharmacy chains, and other pharmaceutical manufacturers in China. The company focuses on various therapeutic areas, including oncology, central nervous system, autoimmune, anti-infection, cardiovascular, and others. Its principal products include Sanbexin, an edaravone and dexborneol concentrated solution for injection; Endostar, a recombinant human endostatin injection; ENWEIDA, an envafolimab injection; ... [Read more]

Sector Healthcare
Founded 1995
Employees 6,584
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2096
Full Company Profile

Financial Performance

In 2024, HKG:2096's revenue was 6.64 billion, an increase of 0.41% compared to the previous year's 6.61 billion. Earnings were 733.17 million, an increase of 2.57%.

Financial numbers in CNY Financial Statements

News

There is no news available yet.